PROFIL ANTIBIOTIK UNTUK PENGOBATAN PASIEN COVID-19 DI SUATU RUMAH SAKIT DI BANDUNG

Authors

  • Ida Lisni Universitas Bhakti Kencana
  • Devi Mujianti Universitas Bhakti Kencana
  • Ani Anggriani Universitas Bhakti Kencana

DOI:

https://doi.org/10.52434/jfb.v12i2.1196

Keywords:

antibiotic, covid-19, SARS-CoV-2

Abstract

Coronavirus disease (Covid-19) merupakan penyakit menular yang disebabkan oleh SARS-Cov2. Organisasi kesehatan dunia (WHO) telah menyatakan penyakit ini sebagai pandemi, dan skala penyebaran penyakit terjadi secara global di seluruh dunia. Dalam penatalaksanaan pasien Covid-19 menggunakan terapi antibiotik. Tujuan penelitian ini untuk mengetahui gambaran terapi antibiotik pada pasien Covid-19. Penelitian ini merupakan studi deskriptif observasional dilakukan secara retrospektif melalui data Kartu Obat Pasien (KOP) 157 pasien dengan diagnosis Covid-19 yang menerima terapi antibiotik selama periode Januari sampai Maret 2021. Hasil penelitian menunjukkan bahwa antibiotik azitromisin yang terbanyak digunakan (40,42%), pemberian kombinasi antibiotik terbanyak yaitu kombinasi azitromisin dan ceftriakson (28,03%), semua pasien menerima antibiotik dengan dosis dan lama terapi yang sesuai. Ditemukan potensi interaksi obat tipe farmakodinamik dengan tingkat keparahan sedang pada penggunaan antibiotik, interaksi obat azitromisin-remdesivir (30,57%), azitromisin-ondansetron (5,73%), dan azitromisin-levofloksasin (38,04%). Perlu peningkatan peran apoteker rumah sakit dalam pemantauan terhadap terapi obat pasien Covid-19 untuk meningkatkan kualitas hidup pasien.

Kata kunci: antibiotik, azitromisin, pengobatan Covid-19

Author Biography

Ida Lisni, Universitas Bhakti Kencana

Dosen Program Studi Pendidikan Apoteker

References

Lukito JI. Tinjauan antivirus untuk terapi Covid-19. J Cermin Dunia Kedokt. 2020; 47(5). p340-45.

Morfi CW. Kajian terkini Corona Virus Disease 2019 (Covid-19). J Ilmu Kesehat Indones. [serial online]. 2020;1(1). p1–8. DOI: 10.25077/jikesi.v1i1.13

Sinto R. Peran penting pengendalian resistensi antibiotik. J Penyakit Dalam. [serial online]. 2020; 7(4). p194-95. DOI: 10.7454/jpdi.v7i4.533

World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. Geneva. 2020. [cited 2020 Nov 20]. Available from: https://www.who.int/docs/default-source/coronaviruse/

Liverpool Drug Interaction Group. Interactions with experimental COVID-19 therapies. Liverpool: University of Liverpool. 2021 [cited 2021 Feb 15]. Available from: https://www.covid19-druginteractions.org/

Susilo A, Rumende CM, Pitoyo CW, et al. Coronavirus disease 2019 tinjauan literatur terkini. J Penyakit Dalam. [serial online]. 2020; 7(1). p45-67. DOI: 10.7454/jpdi.v7i1.415

Siagian TH. Finding high risk groups to coronavirus using discourse network analysis. J Kebijak Kesehat Indones. 2020; 9(2) [cited 2021 May 20]. p98-106. Available from https://jurnal.ugm.ac.id/jkki/issue/view/4202

Katzung BG. Basic and clinical pharmacology, Tenth Edition. Lange Medical Publications, United State.2016. p851-99

PAPDI. Pedoman Tatalaksana Covid-19 Edisi 3. 2020. Jakarta

Donsu YC, Hasmono D. Tinjauan azitromisin pada penyakit virus korona 2019 (Covid-19). Pharmacon: J Farm Indones. 2020; 17 (2). p133-47. DOI:10.23917/pharmacon.v17i2.12359

Gumbo T. General principles of antimicrobial therapy. Goodman and Gilman's the pharmacological basis of therapeutics. 12th ed. New York: The Mc Graw-Hill Companies, Inc. 2011.p1366-380

Metlay J, Waterer G. Treatment of community-acquired pneumonia during the coronavirus disease 2019 (COVID-19) pandemic. Ann Intern Med. 2020.p1-3. DOI: 10.7326/M20-2189

Whalen K. Lippincott illustrated reviews: pharmacology 7th ed. Philadelphia: Lippincott Williams & Wilkins. 2019.p1030-045

American Hospital Formulary Service. AHFS drug information.Bathesda: American Society of Health System Pharmacist (chm version). 2011.

Baxter K. Stockley’s drug interactions 9th edition. Pharm Press, London UK. 2010. p290-91

Lu ZK, Yuan J, Li M, Sutton SS, Rao GA, Jacob S, Bennett CL. Cardiac risks associated with antibiotics: azithromycin and levofloksasin. Expert Opin Drug Saf. 2015; 14(2): p295-03. DOI: 10.1517/14740338.2015.989210

Nurlaelah I, Mukaddas A, Faustine I. Kajian interaksi obat pada pengobatan diabetes melitus (DM) dengan hipertensi di instalasi rawat jalan RSUD Undata periode Maret-Juni tahun 2014. J Farm Galen (Galenika J Pharmacy) (e-Journal). 2015 1(1); p35-41. DOI: 10.22487/j24428744.2015.v1.i1

Utami PR, Handayani RP. (2020), potensi interaksi obat pada pasien geriatri yang menggunakan antihipertensi di Puskesmas Karanggeneng Lamongan. J Surya. 2020; 12 (2): p70-6. DOI:10.38040/js.v12i2.141

Dasopang ES, Harahap U, Lindarto D. Polifarmasi dan interaksi obat pasien usia lanjut rawat jalan dengan penyakit metabolik. J Farm Klin Indones. 2015; 4(4); p235–24. DOI: 10.15416/ijcp.2015.4.4.23

Downloads

Additional Files

Published

2021-07-31

Issue

Vol. 12 No. 2 (2021): Jurnal Ilmiah Farmako Bahari

Section

Research Article

License

or all articles published in Jurnal Ilmiah Farmako Bahari, the copyright is retained by the journal. Articles are published under the terms of Creative Commons Attribution-ShareAlike 4.0 International License (CC-BY-SA 4.0) .

For Authors:

  • Any article on the copyright is retained by the author(s).
  • The author grants the journal, right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share work with an acknowledgment of the work authors and initial publications in this journal.
  • Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of published articles of work (eg, post-institutional repository) or publish it in a book, with acknowledgment of its initial publication in this journal.
  • Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their websites) prior to and during the submission process, as can lead to productive exchanges, as well as earlier and greater citation of published work.
  • The article and any associated published material is distributed under the Creative Commons Attribution-ShareAlike 4.0 International License